No benefit of adjuvant palbociclib in HR+, HER2- breast cancer patients

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 21 / Springer Healthcare

No benefit of adjuvant palbociclib in HR+, HER2- breast cancer patients

Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Oncology Breast Cancer ESMO-2020

Description

Erica Mayer provides a top-line overview of the phase 3 PALLAS trial evaluating the addition of palbociclib to adjuvant endocrine therapy in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.